Bain Capital Acquires Mitsubishi Tanabe Pharma for $3.3 Billion in Strategic Japanese Pharma Investment

Bain Capital has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation (MTPC) for approximately 510 billion JPY ($3.3 billion)12.

The acquisition is structured as a carve-out transaction from Mitsubishi Chemical Group Corporation2.

MTPC, founded in 1678, is one of the oldest pharmaceutical companies in the world, headquartered in Doshomachi, Osaka2.

The investment is led by Bain Capital's Private Equity teams in Asia and North America, along with the firm's Life Sciences team2.

As an independent company, MTPC will focus on several priority therapeutic areas, including immunology & inflammation, vaccines, central nervous system (CNS), diabetes, and metabolic diseases2.

The transaction is expected to close in the third quarter of 2025, subject to customary closing conditions, regulatory clearance, and shareholder approvals2.

Bain Capital sees promising growth opportunities in Japan's life sciences industry, citing government and regulatory initiatives to accelerate the development and approval of innovative medicines2.

The acquisition aligns with Bain Capital's global Healthcare platform, which has experience supporting pharmaceutical companies' growth and innovation2.

MTPC employs over 5,000 people globally and will continue to build on its legacy of medical innovation while developing new growth opportunities2.

The deal represents a significant investment in the Japanese pharmaceutical sector by a leading global private investment firm12.

Sources:

1. https://www.americanpharmaceuticalreview.com/1315-News/617622-Bain-Capital-to-Acquire-Mitsubishi-Tanabe-Pharma-Corporation-for-3-3B/

2. https://www.businesswire.com/news/home/20250207056585/en/Bain-Capital-to-Acquire-Mitsubishi-Tanabe-Pharma-Corporation